Works matching IS 0008543X AND DT 2009 AND VI 115 AND IP 18


Results: 36
    1
    2
    4

    Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

    Published in:
    2009
    By:
    • Kantarjian H;
    • Pasquini R;
    • Lévy V;
    • Jootar S;
    • Holowiecki J;
    • Hamerschlak N;
    • Hughes T;
    • Bleickardt E;
    • Dejardin D;
    • Cortes J;
    • Shah NP;
    • Kantarjian, Hagop;
    • Pasquini, Ricardo;
    • Lévy, Vincent;
    • Jootar, Saengsuree;
    • Holowiecki, Jerzy;
    • Hamerschlak, Nelson;
    • Hughes, Timothy;
    • Bleickardt, Eric;
    • Dejardin, David
    Publication type:
    journal article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    Key Concerns About the Current State of Bladder Cancer.

    Published in:
    Cancer (0008543X), 2009, v. 115, n. 18, p. 4096, doi. 10.1002/cncr.24463
    By:
    • Lotan, Yair;
    • Kamat, Ashish M.;
    • Porter, Michael P.;
    • Robinson, Victoria L.;
    • Shore, Neal;
    • Jewett, Michael;
    • Schelhammer, Paul F.;
    • deVere White, Ralph;
    • Quale, Diane;
    • Lee, Cheryl T.
    Publication type:
    Article
    26
    27
    28
    29
    30
    31
    32
    33
    34

    CLINICAL TRIALS OF NOTE.

    Published in:
    Cancer (0008543X), 2009, v. 115, n. 18, p. 4044, doi. 10.1002/cncr.24648
    Publication type:
    Article
    35
    36

    Untitled.

    Published in:
    Cancer (0008543X), 2009, v. 115, n. 18, p. 4044, doi. 10.1002/cncr.24646
    Publication type:
    Article